- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
New In-Depth Informative Website Launched for People With Psoriasis and Psoriatic Arthritis
—
ST ALBANS, England, May 1ST ALBANS, England, May 1 /PRNewswire/ -- On the 1st of May 2008, UK charity, the Psoriasis and Psoriatic Arthritis Alliance (PAPAA) is launching its new website http://www.papaa.org under the banner of The Principal Source of Information for Psoriasis and Psoriatic Arthritis. PAPAA is providing an up-to-date resource that will give people with the latest information about the condition along with what treatments are available and useful articles.
PAPAA is independently funded and doesn't receive financial support from the commercial or pharmaceutical industry. The site is managed by PAPAA with real input from people with or affected by psoriasis and psoriatic arthritis.
David Chandler PAPAA CEO said "We've been working hard on the site for sometime and want to provide something different than the usual flat paged sites. We want the user to have a 'conversation', so the answers appear as links, just as though the site is anticipating the questions."
The site is free to use, has it own search facility, and all medical material has been written by, or approved by doctors. Users who register can add comments or suggest FAQs, there is even a facility to submit articles.
"We want this site to be a community based site that gives real people real input in the content. Psoriasis and psoriatic arthritis can both be confusing and demoralising; we want to provide a positive approach to disease management. This site is the first part of that process. We won't be endorsing products but want to provide a comprehensive range of information to educate people affected by these conditions" added David.
Notes to editors:
Psoriasis affects 2% of the UK population and is a chronic skin disease which appears as red scaly patches, causing individuals to become socially embarrassed often suffering discrimination and lack of self confidence.
Psoriatic arthritis affects 10-20% of people with psoriasis and can in some cases cause permanent disability. There can sometimes be confusion in diagnosis as there is no specific test to determine the existence of the disease. Diagnosis relies on other factors to be present, such as skin involvement.
Pictures and images are available electronically.
About PAPAA:
PAPAA was founded in 2007, as a joint venture between the Psoriatic Arthropathy Alliance (PAA) (Reg Charity No: 3055414), and the Psoriasis Support Trust (PST) (Reg Charity No: 1088359), with the aim of merging the original charities into a single entity, becoming a principle resource of information and help for people with psoriasis and psoriatic arthritis in the UK.
The Psoriasis and Psoriatic Arthritis Alliance (PAPAA) is a Registered Charity No:11188192. A Company Limited by Guarantee, registered in England and Wales No: 6074887 Registered Office: Acre House 11-15 William Road London NW1 3ER.
David Chandler is available for interview, by contacting the PAPAA office on +44(0)870-7703212. The organisation can be contacted by the same number or via email at info@papaa.org or by post to PAPAA PO Box 111, St Albans, Herts AL2 3JQ.
Related news
Related News
- New In-Depth Informative Website Launched for People With Psoriasis and Psoriatic Arthritis
- Psoriasis - A Summer Misery for a Silent Minority
- European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel(R) for Patients With Moderate-to-Severe Psoriasis
- New, Informative EAU Website Launched: http://www.urologyweek.org
- Data Presented at International Psoriasis Meeting Support Potential New Role for Biologic Treatment Etanercept in Management of Childhood Psoriasis
- Data Presented at International Psoriasis Meeting Support Potential New Role for Biologic Treatment Etanercept in Management of Childhood Psoriasis
- New Evidence Advocates the use of Enbrel to Combat and Effectively Control the Debilitating Symptoms of Psoriasis
- Leading Rheumatologists Agree Clinical Remission a Key Goal in Rheumatoid Arthritis
- New Data Supports the Safety Record of ENBREL(R) as a Continuous Therapy in Children and Adolescents With Juvenile Idiopathic Arthritis
- NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
Latest News
- Enigma Diagnostics Launches Field Laboratory (FL) System, Fully Automated Real-Time PCR for In-Field Testing
- Shire Plc: Investor Seminar
- Nanion Increases Throughput and Cuts Costs With a New Industrial 96-Channel Patch Clamp Screening Robot
- BT e-Health Insider Awards
- IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)
- NEC Display Solutions Europe Selects Matrox Xenia(TM) Series for Its Color and Grayscale Medical Displays
- Frost & Sullivan Recognises Cosucra's Superior Brand Leadership
- Avantium Introduces Novel Corrosion Assessment Technology
- Avantium Further Strengthens its Pharma Business Development Team
- Quest Diagnostics' Laboratory in India Accredited by Two Leading Laboratory Accrediting Organizations
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us